BRIACELL THERAPEUTICS CORP. Directors Remuneration Expense
BRIACELL THERAPEUTICS CORP. (BCTX) reported Directors Remuneration Expense of $1.17 million for the 3-month period ending 2022-04-30, per its 6-K filed 2022-06-13.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:DirectorsRemunerationExpense · last filed 2022-06-13
- BRIACELL THERAPEUTICS CORP. directors remuneration expense for the quarter ending 2022-04-30 was $1.17M, a 31.61% decline year-over-year.
- BRIACELL THERAPEUTICS CORP. directors remuneration expense for the quarter ending 2022-01-31 was $1.05M.
- BRIACELL THERAPEUTICS CORP. directors remuneration expense for the quarter ending 2021-07-31 was $2.00.
- BRIACELL THERAPEUTICS CORP. directors remuneration expense for the quarter ending 2021-04-30 was $1.71M.
| Period end | Directors Remuneration Expense 3 month | Directors Remuneration Expense 6 month | Directors Remuneration Expense 9 month | Directors Remuneration Expense 12 month |
|---|---|---|---|---|
| 2022-04-30 | $1.17M 6-K · filed 2022-06-13 | $2.22M derived: sum of 2 quarters · filed 2022-06-13 | $2.22M 6-K · filed 2022-06-13 | |
| 2022-01-31 | $1.05M 6-K · filed 2022-03-15 | $1.05M 6-K · filed 2022-03-15 | ||
| 2021-07-31 | $2.00 derived: 40-F/A 12 month − 6-K 9 month · filed 2021-11-16 | $1.71M derived: sum of 2 quarters · filed 2022-06-13 | $1.71M 40-F/A · filed 2021-11-16 | |
| 2021-04-30 | $1.71M 6-K · filed 2022-06-13 | $1.71M 6-K · filed 2022-06-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |